Spero Q2 net loss widens to $28.7M; tebipenem HBr NDA receives CRL; Phase 2 SPR720 trial set for Q4 2022

Spero Therapeutics, Inc.

2022-Q2 EPS reported -$1.88 revenue$4,062,000

Net loss $28.7M ($0.87/share) vs $18.6M ($0.63/share) in Q2 2021; revenue $2.0M down from $5.1M.
FDA issued Complete Response Letter for tebipenem HBr NDA; Type A meeting completed to discuss path forward.
Phase 2 trial of SPR720 in NTM-PD expected to start Q4 2022; interim data mid-2023.
SPR206 regulatory milestone achieved under Pfizer license; $5M payment expected in Q3 2022.
Cash, equivalents and marketable securities $45.4M; believes funding into late 2023 via restructuring.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.